Anti-phage serum antibody responses and the outcome of phage therapy
- PDF / 229,363 Bytes
- 5 Pages / 595.276 x 790.866 pts Page_size
- 31 Downloads / 188 Views
SHORT COMMUNICATION
Anti-phage serum antibody responses and the outcome of phage therapy M. Łusiak-Szelachowska 1 & R. Międzybrodzki 1,2,3 & W. Fortuna 1,2,4 & J. Borysowski 3 & Andrzej Górski 1,2,5 Received: 3 August 2020 / Accepted: 22 October 2020 # The Author(s) 2020
Abstract We examined the appearance of serum anti-phage antibodies in 25 patients with chronic sinusitis treated with phage therapy (PT). Approximately 30% of patients with weak antibody responses responded positively to PT, which was similar to the results of treatment achieved in a group of patients with high antibody production. In addition, there was no correlation between antibody level and the outcome of PT. These data, derived from a homogenous group of patients, confirm our earlier findings suggesting that the prognostic significance of serum anti-phage antibodies for the outcome of PT should be determined by relevant clinical trials.
Introduction The growing menace of antibiotic resistance has greatly revived interest in phage therapy (PT). In the past few years, a number of reports have been published strongly suggesting that the PT—alone or in association with antibiotics—may be an efficient means of combating multidrug-resistant bacteria. Some authors believe that antibiotic marketplace is broken and that the therapy with bacterial viruses has the potential to be used in the treatment of infectious diseases either alone or as adjuvants to existing therapies (Safir et al. 2020). A number of clinical trials are currently underway which suggests that the real value of PT should eventually be determined
* Andrzej Górski [email protected] 1
Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (HIIET PAS), Wrocław, Poland
2
Phage Therapy Unit, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (HIIET PAS), Wrocław, Poland
3
Department of Clinical Immunology, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland
4
Department of Neurosurgery, Wrocław Medical University, Wrocław, Poland
5
Infant Jesus Hospital, Medical University of Warsaw, Warsaw, Poland
according to currently required standards of evidence-based medicine. Phages—as other viruses—may interact with the immune system. Such interactions can lead to anti-phage antibody responses as well as cause immunomodulating effects. In the past years, phage-mediated immunomodulation has received increasing attention. Phage-dependent immunomodulating effects may have therapeutic potential in disorders of the immune system and alleviation of allograft reactivity as well as treatment of some non-bacterial infections (Górski et al. 2019a). Our studies have supplied some data on anti-phage humoral responses of mice receiving phages as well as phage proteins using different routes of phage administration and duration of p hage treatment (Dąbro w ska 2 019 ). Furthermore, we studied anti-phage antibody formation in patients receiving PT (Łusiak-Szelachowska et al.
Data Loading...
